Veru Announces Full Enrollment for Phase 2b PLATEAU Clinical Trial of Enobosarm and Semaglutide Combination for High Quality Weight Loss

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 8/11/2026

1. RKLB
2. ACVA
3. RIOT
4. RPD
5. HIMS
6. NVDA
7. UPWK
8. PLUG
9. SPY
10. PAL

Go back to Veru Announces Full Enrollment for Phase 2b PLATEAU Clinical Trial of Enobosarm and Semaglutide Combination for High Quality Weight Loss
(NASDAQ: VERU) Delayed: 2.77 --0 (-0%)
Previous Close $2.77    52 Week High $ 
Open $2.77    52 Week Low $ 
Day High $2.77    P/E N/A 
Day Low $2.77    EPS $ 
Volume 1,231